pioglitazone


Also found in: Medical, Wikipedia.

pi·o·glit·a·zone

 (pī′ō-glĭt′ə-zōn′)
n.
A thiazolidinedione drug, C19H20N2O3S, used in its hydrochloride form to treat type 2 diabetes.
[pio-, origin unknown + -glitazone, thiazolidinedione suff.; see rosiglitazone.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

pioglitazone

n pioglitazona
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
A NASH TAG presentation in January 2019 highlighted data in which PXL065 was observed to have a more favorable profile versus pioglitazone and other thiazolidinediones (TZDs).
Poxel Reports Financial Results for First Half 2019 and Provides Corporate Update
Pioglitazone, a derivative of thiazolidinedione, is a PPARI3 agonist used in the treatment of individuals with type 2 diabetes (Kota et al., 2005).
Pioglitazone Mediated Reduction in Oxidative Stress and Alteration in Level of PPARI3, NRF2 and Antioxidant Enzyme Genes in Mouse Preimplantation Embryo during Maternal to Zygotic Transition
It adds, "Because some NASH patients are treated with vitamin E or pioglitazone, enrollment of such patients in clinical trials may confound treatment effects.
FDA posts draft guidance for developing NASH drugs
Poxel, a biopharmaceutical company, has commenced part two of the phase 1a study for PXL065, a deuterium-stabilised R-stereoisomer of pioglitazone intended for the treatment of non-alcoholic steatohepatitis (NASH), it was reported yesterday.
Poxel starts PXL065 part two phase 1a studyPoxel starts PXL065 part two phase 1a study
The remaining two were used as interventional groups and received either pioglitazone or aliskerin for four weeks after induction of diabetes.
ALISKERIN: A DIRECT RENIN INHIBITOR IMPROVES PANCREATIC FUNCTIONAL B CELL MASS IN TYPE 2 DIABETIC MICE
PIOGLITAZONE THERAPY given for 18 months benefited patients with nonalcoholic steatohepatitis (NASH) similarly regardless of whether they had type 2 diabetes mellitus or prediabetes, according to the results of a randomized prospective trial.
Pioglitazone benefited NASH patients with and without T2DM
Pioglitazone, which works on reversing almost all mechanisms involved in the pathogenesis, is the new suggested preventive option in this study.
The Preventive Role of Pioglitazone in Glycerol-Induced Acute Kidney Injury in Rats during Two Different Treatment Periods
Pioglitazone is a special ligand of peroxisome proliferators-activated receptor-[gamma] (PPAR-[gamma]).
Therapeutic effect and potential mechanism of pioglitazone in rats with severe acute pancreatitis
PPAR-[gamma] agonist- (pioglitazone) attenuated upper airway allergic inflammation may be mediated by the induction of Tregs [14].
PPAR-[gamma] Agonist Alleviates Liver and Spleen Pathology via Inducing Treg Cells during Schistosoma japonicum Infection
Moreover, preclinical studies conducted both in vitro and in vivo have provided the evidence of anticancer properties of particular PPAR-[gamma] agonists, rosiglitazone and pioglitazone. Several studies demonstrating rosiglitazone and pioglitazone on Pomc suppression have been done [12, 18, 19], and an opposite effect of rosiglitazone was also shown by Kreutzer et al.
Inhibitory Effects of a Novel PPAR-[gamma] Agonist MEKT1 on Pomc Expression/ACTH Secretion in AtT20 Cells
Previous studies have shown that several drugs, including metformin, rosiglitazone, and pioglitazone, can control high blood glucose levels and protect patients from diabetes-related complications [3].
Identification of Potential Therapeutic Targets in the Liver of Pioglitazone-Treated Type 2 Diabetes Sprague-Dawley Rats via Expression Profile Chip and iTRAQ Assay
Objective: To determine the effect of pioglitazone on cardiometabolic risk factors in non-diabetic patients with dyslipidaemia.
Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia
Dictionary browser ?
Full browser ?